{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:46:18Z","timestamp":1761864378605},"reference-count":16,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2022,4,1]]},"DOI":"10.1001\/jamaoncol.2021.7777","type":"journal-article","created":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T16:31:54Z","timestamp":1641573114000},"page":"612","source":"Crossref","is-referenced-by-count":36,"title":["SARS-CoV-2 Antibody Response to 2 or 3 Doses of the BNT162b2 Vaccine in Patients Treated With Anticancer Agents"],"prefix":"10.1001","volume":"8","author":[{"given":"Charlotte","family":"Fenioux","sequence":"first","affiliation":[{"name":"University Paris Est Cr\u00e9teil, INSERM U955, IMRB, Cr\u00e9teil, France"},{"name":"AP-HP, H\u00f4pital Henri Mondor, Service d\u2019oncologie m\u00e9dicale, Cr\u00e9teil, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Teixeira","sequence":"additional","affiliation":[{"name":"University de Paris, AP-HP, H\u00f4pital Saint-Louis, Breast Disease Center, INSERM U976, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Slim","family":"Fourati","sequence":"additional","affiliation":[{"name":"University Paris Est Cr\u00e9teil, INSERM U955, IMRB, Cr\u00e9teil, France"},{"name":"AP-HP, H\u00f4pital Henri Mondor, Service de virologie, Cr\u00e9teil, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Melica","sequence":"additional","affiliation":[{"name":"University Paris Est Cr\u00e9teil, INSERM U955, IMRB, Cr\u00e9teil, France"},{"name":"AP-HP, H\u00f4pital Henri Mondor, Service d\u2019immunologie clinique et maladies infectieuses, Cr\u00e9teil, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Daniel","family":"Lelievre","sequence":"additional","affiliation":[{"name":"University Paris Est Cr\u00e9teil, INSERM U955, IMRB, Cr\u00e9teil, France"},{"name":"AP-HP, H\u00f4pital Henri Mondor, Service d\u2019immunologie clinique et maladies infectieuses, Cr\u00e9teil, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastien","family":"Gallien","sequence":"additional","affiliation":[{"name":"University Paris Est Cr\u00e9teil, INSERM U955, IMRB, Cr\u00e9teil, France"},{"name":"AP-HP, H\u00f4pital Henri Mondor, Service d\u2019immunologie clinique et maladies infectieuses, Cr\u00e9teil, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e9rard","family":"Zalcman","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, AP-HP, H\u00f4pital Bichat-Claude Bernard, Service d\u2019oncologie thoracique and CIC INSERM 1425, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Michel","family":"Pawlotsky","sequence":"additional","affiliation":[{"name":"University Paris Est Cr\u00e9teil, INSERM U955, IMRB, Cr\u00e9teil, France"},{"name":"AP-HP, H\u00f4pital Henri Mondor, Service de virologie, Cr\u00e9teil, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Tournigand","sequence":"additional","affiliation":[{"name":"University Paris Est Cr\u00e9teil, INSERM U955, IMRB, Cr\u00e9teil, France"},{"name":"AP-HP, H\u00f4pital Henri Mondor, Service d\u2019oncologie m\u00e9dicale, Cr\u00e9teil, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"key":"cbr210021r1","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ejca.2021.03.030","article-title":"Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER).","volume":"150","author":"Tougeron","year":"2021","journal-title":"Eur J Cancer"},{"key":"cbr210021r2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ejca.2021.06.008","article-title":"Current perspectives for SARS-CoV-2 vaccination efficacy improvement in patients with active treatment against cancer.","volume":"154","author":"Barri\u00e8re","year":"2021","journal-title":"Eur J Cancer"},{"issue":"10","key":"cbr210021r4","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1001\/jamaoncol.2021.2675","article-title":"Serologic status and toxic effects of the SARS-CoV-2 BNT162b2 vaccine in patients undergoing treatment for cancer.","volume":"7","author":"Goshen-Lago","year":"2021","journal-title":"JAMA Oncol"},{"issue":"7","key":"cbr210021r6","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1056\/NEJMc2108861","article-title":"Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients.","volume":"385","author":"Kamar","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"cbr210021r7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41416-020-0843-5","article-title":"Caring for our cancer patients in the wake of COVID-19.","volume":"123","author":"El-Shakankery","year":"2020","journal-title":"Br J Cancer"},{"issue":"11","key":"cbr210021r8","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1001\/jamaoncol.2021.4390","article-title":"Durability of response to SARS-CoV-2 BNT162b2 vaccination in patients on active anticancer treatment.","volume":"7","author":"Eliakim-Raz","year":"2021","journal-title":"JAMA Oncol"},{"issue":"10","key":"cbr210021r9","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1158\/2159-8290.CD-21-1072","article-title":"Six-month efficacy and toxicity profile of BNT162B2 vaccine in cancer patients with solid tumors.","volume":"11","author":"Waldhorn","year":"2021","journal-title":"Cancer Discov"},{"issue":"8","key":"cbr210021r10","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.ccell.2021.06.002","article-title":"Seroconversion rates following COVID-19 vaccination among patients with cancer.","volume":"39","author":"Thakkar","year":"2021","journal-title":"Cancer Cell"},{"issue":"4","key":"cbr210021r11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2020.12.014","article-title":"Optimal timing for COVID-19 vaccination in oncology patients receiving chemotherapy?","volume":"33","author":"Sudan","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"7","key":"cbr210021r12","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"key":"cbr210021r13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.647934","article-title":"A structural landscape of neutralizing antibodies against SARS-CoV-2 receptor binding domain.","volume":"12","author":"Niu","year":"2021","journal-title":"Front Immunol"},{"issue":"6","key":"cbr210021r14","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/s41591-021-01325-6","article-title":"Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2.","volume":"27","author":"Ebinger","year":"2021","journal-title":"Nat Med"},{"issue":"11","key":"cbr210021r15","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","article-title":"Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.","volume":"27","author":"Feng","year":"2021","journal-title":"Nat Med"},{"issue":"7871","key":"cbr210021r16","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","article-title":"Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.","volume":"596","author":"Planas","year":"2021","journal-title":"Nature"},{"key":"cbr210021r3","doi-asserted-by":"crossref","unstructured":"Gounant? V, Ferr\u00e9? VM, Soussi? G, . Efficacy of SARS-CoV-2 vaccine in thoracic cancer patients: a prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses.? medRxiv. Preprint posted August 13, 2021. doi:10.1101\/2021.08.12.21261806?","DOI":"10.1101\/2021.08.12.21261806"},{"key":"cbr210021r5","doi-asserted-by":"crossref","unstructured":"Gallais? F, Gantner? P, Bruel? T, . Anti-SARS-CoV-2 antibodies persist for up to 13 months and reduce risk of reinfection.? medRxiv. Preprint posted May 17, 202 . doi:10.1101\/2021.05.07.21256823?","DOI":"10.1101\/2021.05.07.21256823"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2788011\/jamaoncology_fenioux_2022_br_210021_1650482127.71103.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T15:30:19Z","timestamp":1650555019000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2788011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2021.7777","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,1]]}}}